Literature DB >> 23664521

Innate and adaptive immunity in immune thrombocytopenia.

Alan H Lazarus1, John W Semple, Douglas B Cines.   

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by both accelerated clearance of autoantibody-sensitized platelets and suboptimal platelet production. A number of studies have provided evidence of disturbed innate and adaptive immune responses in patients with ITP. This brief review will highlight some of the more recent work in this field and highlight other findings that provide a potential link between ITP, systemic lupus erythematosus (SLE), and autoimmune hemolytic anemia (AHA).
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 23664521      PMCID： PMC3691820          DOI： 10.1053/j.seminhematol.2013.03.012

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  15 in total

Review 1.  'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants.

Authors:  Yehuda Shoenfeld; Nancy Agmon-Levin
Journal:  J Autoimmun       Date:  2010-08-13       Impact factor: 7.094

Review 2.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 3.  Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production.

Authors:  Robert McMillan
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

4.  Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies.

Authors:  Michelle Lee Webster; Ebrahim Sayeh; Min Crow; Pingguo Chen; Bernhard Nieswandt; John Freedman; Heyu Ni
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

5.  A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy.

Authors:  Leola Chow; Rukhsana Aslam; Edwin R Speck; Michael Kim; Norman Cridland; Michelle Lee Webster; Pingguo Chen; Kim Sahib; Heyu Ni; Alan H Lazarus; M Bernadette Garvey; John Freedman; John W Semple
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

6.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

7.  CD16+ monocytes control T-cell subset development in immune thrombocytopenia.

Authors:  Hui Zhong; Weili Bao; Xiaojuan Li; Allison Miller; Caroline Seery; Naznin Haq; James Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

8.  Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.

Authors:  Roberto Stasi; Nichola Cooper; Giovanni Del Poeta; Elisa Stipa; Maria Laura Evangelista; Elisabetta Abruzzese; Sergio Amadori
Journal:  Blood       Date:  2008-03-28       Impact factor: 22.113

Review 9.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

10.  Direct contact of platelets and their released products exert different effects on human dendritic cell maturation.

Authors:  Hind Hamzeh-Cognasse; Fabrice Cognasse; Sabine Palle; Patricia Chavarin; Thomas Olivier; Olivier Delézay; Bruno Pozzetto; Olivier Garraud
Journal:  BMC Immunol       Date:  2008-09-25       Impact factor: 3.615
View more
  6 in total

1.  Human megakaryocyte progenitors derived from hematopoietic stem cells of normal individuals are MHC class II-expressing professional APC that enhance Th17 and Th1/Th17 responses.

Authors:  Ariel Finkielsztein; Alaina C Schlinker; Li Zhang; William M Miller; Syamal K Datta
Journal:  Immunol Lett       Date:  2014-11-29       Impact factor: 3.685

2.  Contributions of T lymphocyte abnormalities to therapeutic outcomes in newly diagnosed patients with immune thrombocytopenia.

Authors:  Zhenhua Zhao; Lei Yang; Guohua Yang; Yun Zhuang; Xifeng Qian; Xin Zhou; Dajiang Xiao; Yunfeng Shen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

3.  Association of CD4(+)CD25(+)FoxP3(+) regulatory T cells with natural course of childhood chronic immune thrombocytopenic purpura.

Authors:  Bo Ra Son; Ji Yoon Kim
Journal:  Korean J Pediatr       Date:  2015-05-22

4.  Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia.

Authors:  Lili Tao; Qingshu Zeng; June Li; Miao Xu; Jiajia Wang; Ying Pan; Huiping Wang; Qianshan Tao; Yang Chen; Jun Peng; Ming Hou; Arend Jan Gerard Jansen; Heyu Ni; Zhimin Zhai
Journal:  J Hematol Oncol       Date:  2017-02-08       Impact factor: 17.388

Review 5.  Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP).

Authors:  Anne Zufferey; Rick Kapur; John W Semple
Journal:  J Clin Med       Date:  2017-02-09       Impact factor: 4.241

6.  Pathomechanisms of HIV-Associated Cerebral Small Vessel Disease: A Comprehensive Clinical and Neuroimaging Protocol and Analysis Pipeline.

Authors:  Kyle D Murray; Meera V Singh; Yuchuan Zhuang; Md Nasir Uddin; Xing Qiu; Miriam T Weber; Madalina E Tivarus; Henry Z Wang; Bogachan Sahin; Jianhui Zhong; Sanjay B Maggirwar; Giovanni Schifitto
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.